Oxaliplatin + Irofulven
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Liver Cancer
Conditions
Liver Cancer
Trial Timeline
Jun 1, 2003 → Apr 1, 2007
NCT ID
NCT00374660About Oxaliplatin + Irofulven
Oxaliplatin + Irofulven is a phase 1/2 stage product being developed by Eisai for Liver Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00374660. Target conditions include Liver Cancer.
What happened to similar drugs?
9 of 20 similar drugs in Liver Cancer were approved
Approved (9) Terminated (0) Active (11)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00374660 | Phase 1/2 | Completed |
Competing Products
20 competing products in Liver Cancer